创新浪潮奔涌向前，出海征程再启新篇。9月26-29日，BiG将召开以「创新出海 云起潮升」为主题的第十一届IMPACT年会，上海杭州双城联动，向全球化，再出发！本次年会将汇聚全球顶尖投资人、NewCo公司创始人、行业权威专家及领军企业家，共同构建跨界学习与资源共享的深度交流平台，在思维激荡中探寻产业创新机遇。

届时全球顶级投资机构RA Capital将受邀出席第十一届BiG IMPACT年会。RA Capital 是全球生物医药领域最活跃的基金之一，2024年投资49家Biotech 公司，资金注入高达56.6亿美元，位居全球榜首。其投资的Moderna、Arvinas、AveXis、Biohaven、Dicerna和Juno Therapeutics等企业，在行业内影响力巨大 。

RA Capital可为企业提供从种子轮直至IPO全流程的资本支持，凭借由顶尖科学家构建的TechAtlas研究体系，深度剖析技术发展趋势与临床设计要点，助力初创企业成功跨越从科学成果到商业价值转化的关键历程 。

● 主论坛：全球化，再出发

全球资本视角：生物医药投资的新地理版图

Josh Resnick, MD,Partner of RA Capital Management

● 分论坛1：突破传统，创新Modalities

Opening Insights：

Breanna O'Reilly, PhD, Senior AssociatePartner of RA Capital Management

● 分论坛4：MNC战略与全球VC视角：资本如何撬动出海

Panel 全球视野下的生物医药投资突围与价值创造

Tess Cameron, Principal, Partner of RA Capital Management (Panelist) 

● 分论坛6：1v1资本对接会（speed dating）

1v1资本对接会 

路演项目征集

可扫码填写项目信息

现场开放1v1咨询台，与各大头部VC面对面

▼

电脑端链接：https://event.mymova.com/spa4/#/?eventname=11bigvc

  RA Capital 嘉宾介绍  

* 以下按论坛顺序排列

Josh Resnick

MD, Partner

Josh Resnick is a Partner at RA Capital Management. Josh’s primary responsibility is to lead early-stage private investments in and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. Josh was previously co-lead of SV Health Investors’ US Biotech practice where he was responsible for SV’s US venture creation activities, including its incubator, Brahma Discovery. Before SV, Josh was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund within Merck & Co. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business.

Breanna O'Reilly

PhD, Senior Associate

Breanna O’Reilly is a Senior Associate with the TechAtlas division of RA Capital Management. Breanna's primary responsibilities are to work closely with members of the investment team and portfolio companies to deeply understand competitive landscapes, evaluate investment opportunities in a variety of therapeutic areas across all stages from discovery and new company creation through commercialization, and advise portfolio companies on program and pipeline strategy. Prior to RA, Breanna was an Analyst at Boston University Office of Technology Development and a Consultant for Tufts Advisory Partners. Breanna holds a BS in Biomedical Engineering from University of Rochester and a PhD in Biomedical Engineering from Boston University.

Tess Cameron

Principal

Tess Cameron is a Principal on the Investment Team at RA Capital Management. Tess works on both public and private investments and serves on several company boards. Previously, Tess held finance leadership roles at Foghorn Therapeutics, Wave Life Sciences, and Biogen. Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey & Co, focused on corporate transactions. Tess holds a BA with a double major in Economics and Peace & Conflict studies from the University of Toronto, Canada.

  关于 RA Capital  

RA Capital Management is a leading life sciences investment manager with ~$10b in assets under management and >200 portfolio companies. 

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, allowing management teams to drive value creation from inception through commercialization. 

RA Capital also partners with entrepreneurs to build companies. Our team of experienced company creators and drug developers has launched dozens of companies and can put our expertise and resources at your disposal – including our internal research division, TechAtlas, which provides encyclopedic knowledge of the biopharmaceutical industry.

At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides market intelligence, technical diligence, and other resources to both our internal Investment Team and our portfolio companies. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, and public market dynamics.